Final Thoughts on the Treatment of EGFR-Mutant NSCLC: Balancing Safety and Efficacy, and the Importance of Incorporating Supportive Care Strategies

Video content above is prompted by the following:

Closing Thoughts and Key Take-Home Messages

Key Themes:

• New Standard of Care: Both experts agree combinations represent the new standard for most patients
• Toxicity Management: Critical importance of prophylactic approaches, particularly for amivantamab-based regimens
• Patient Education: Need for thorough patient education and support through treatment

Notable Insights:

• Dr Dietrich: Emphasized the need to “get really good at managing on-target toxicity” and “implementing prophylactic measures about forming networks with dermatology and other specialties.” He acknowledged that “we have an affinity to a single agent or osimertinib, but I think we have to just face reality, that this relatively easy one-size-fits-all option doesn’t meet 2025 expectations anymore.”
• Dr Piotrowska: Highlighted specific prophylactic approaches, including “dexamethasone premedications to prevent infusion reactions, the dermatologic prophylaxis, which includes a tetracycline antibiotic for the first 12 weeks” and “[venous thromboembolism] prophylaxis... recommended for the first 4 months of treatment” with amivantamab plus lazertinib.